Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
HyPer
100%
Polymerase
100%
Chemotherapy Resistance
100%
Nivolumab
100%
MSH6
100%
Endometrial Tumor
100%
Radiotherapy
66%
Clinical Response
66%
Tumor mutation Burden
66%
Anti-PD-1
66%
PD-1 Immune Checkpoint Inhibitor
66%
Chemotherapy
33%
Gene mutation
33%
Therapeutic Potential
33%
Treatment Options
33%
Salvage Treatment
33%
Human Tumors
33%
Novel Treatments
33%
Recurrent Disease
33%
Conventional Chemotherapy
33%
DNA Polymerase
33%
Heavily Pretreated Patients
33%
Endometrial Carcinoma
33%
Recurrent Metastatic
33%
Alternative Therapeutics
33%
High Side
33%
Exonuclease Domain
33%
Anti-PD-1 Inhibitors
33%
MSH6 Gene
33%
Medicine and Dentistry
Neoplasm
100%
Polymerase
100%
Nivolumab
100%
Endometrium Tumor
100%
Chemotherapy
100%
Radiation Therapy
66%
Immune Checkpoint Inhibitor
66%
Mutational Load
66%
Recurrent Disease
33%
Gene Mutation
33%
Side Effect
33%
Endometrium Carcinoma
33%
DNA Polymerase
33%
Exonuclease
33%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Chemotherapy
100%
Nivolumab
100%
Endometrium Tumor
100%
Immune Checkpoint Inhibitor
66%
Side Effect
33%
Recurrent Disease
33%
DNA Polymerase
33%
Endometrium Carcinoma
33%
Exonuclease
33%
Biochemistry, Genetics and Molecular Biology
Polymerase
100%
Immune Checkpoints
100%
MSH6
100%
Mutational Load
100%
Gene Mutation
50%
DNA Polymerase
50%
Exonuclease
50%